Pirtobrutinib for Relapsed/Refractory MCL

home / approval-alert / pirtobrutinib-for-relapsed-refractory-mcl

Pirtobrutinib for Relapsed/Refractory MCL

Articles
The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.

FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed/Refractory MCL

January 27th 2023

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.